Senators urge action to block drastic drug price hikes

December 21, 2016 by Matthew Perrone

Angered by skyrocketing drug prices, a pair of senators on Wednesday urged Congress to block companies from cornering the market on old, off-patent drugs.

Sens. Susan Collins, R-Maine, and Claire McCaskill, D-Mo., released findings from a year-long investigation into companies like Turing Pharmaceuticals, which generated national outrage last year after hiking the price of a life-saving anti-infection drug by more than 5,000 percent.

Committee investigators concluded that Turing and several other companies "engaged in price gouging ... to make massive profits from decades-old life-saving therapies." The lawmakers, top members of the Special Committee on Aging, presented similar findings at three hearings over the past year.

The 131-page report comes as lawmakers and pharmaceutical executives try to gauge President-elect Donald Trump's interest in government intervention to curb rising drug prices, a leading health care concern among patients.

While campaigning, Trump said he would support efforts to allow Medicare—the massive government health plan for seniors—to directly negotiate drug prices with manufacturers, a step long opposed by the pharmaceutical lobby. That policy does not appear among the health care proposals currently outlined on Trump's website. The list includes a policy allowing importation of cheaper drugs from Canada and other countries, another proposal opposed by drugmakers.

Representatives for Trump did not respond to requests for comment Wednesday.

A day earlier, 19 senators sent a letter to Trump, urging him to follow-through on pledges to help lower drug prices.

"During your campaign, you promised to implement bold reforms to bring down the cost of prescription drugs," states the letter, signed by 17 Democrats and independent Sens. Bernie Sanders of Vermont and Angus King of Maine. "We are ready to advance bipartisan reforms that will help achieve the goal we all share: reducing the burden exorbitant drug prices are placing on hard-working Americans.

The new report draws similarities between the tactics of companies such as Turing and Valeant Pharmaceuticals and investment firms that profit by buying under-valued stocks and pushing up prices. Investigators note that Turing's former CEO, Martin Shkreli, and several other executives probed by the committee previously worked at hedge funds.

"This may help explain why these companies may have been run more like hedge funds than pharmaceutical companies," the report states.

Shkreli stepped down as the head of Turing after prosecutors charged him with securities fraud late last year. Valeant is the target of more than 10 government probes, plus multiple shareholder lawsuits.

Turing said in a statement Wednesday that it has taken several steps to increase access to its drug, daraprim, including offering discounts to hospitals. The drug still carries a list price of $750 per pill.

"It is disappointing that the report takes out of context and selectively highlights certain comments, including from past employees that are not reflective of Turing's current commitments and efforts," the company said.

A Valeant spokesperson did not immediately respond to a request for comment.

An AP analysis published last month found that congressional investigations have had little effect on drug prices. A review of nearly 30 brand-name and generic medications targeted by Congress—including those probed by the Aging committee—showed that most have not budged since coming under federal scrutiny.

Many pharmaceutical companies increase prices annually as a matter of doing business. But the drastic increases profiled in the report helped turn drug pricing into a national issue, reverberating from late-night television to the campaign. The tactics seemed to confirm some of the public's worst fears about pharmaceutical companies: that they are more Wall Street-driven investment vehicles than actual makers of medicines.

"We've got to find ways to increase competition for medicines and ensure that patients and their families aren't being gouged," said McCaskill.

McCaskill and Collins call for several legislative steps intended to increase price competition, including giving priority review to drugmakers that develop cheaper versions of drugs that are only available from a single company. Elsewhere, lawmakers favor short-term importation of drugs in short supply to help bring down U.S. prices.

Explore further: Drug prices don't budge even after pressure from Congress

Related Stories

Drug prices don't budge even after pressure from Congress

November 16, 2016
Congress's routine of publicly shaming drug company executives over high prices works no better than a placebo: It may make some people feel better, but it doesn't treat the problem.

Another drug company in the crosshairs of Congress

March 29, 2016
Another pharmaceutical company is being targeted by lawmakers over drug pricing.

Federal prosecutors accuse execs of fixing drug prices

December 14, 2016
Federal prosecutors have charged two former pharmaceutical executives with fixing prices of generic drugs, part of an ongoing government investigation into anticompetitive tactics by companies that make lower-cost drugs intended ...

Senate panel investigates drug price hikes

November 4, 2015
A Senate committee tasked with protecting seniors is launching an investigation into prescription drug pricing, responding to public anxiety about companies hiking prices for once-inexpensive medicines.

Pricey prostate cancer drug's makers targeted by Congress

March 29, 2016
Lawmakers again are targeting the pharmaceutical industry over sky-high prescription drug prices, a hot issue this year in Washington and on the campaign trail that's been dragging down stock prices of many drugmakers.

Congress: drugmakers planned price hikes to boost profits

February 2, 2016
Two drugmakers have made a practice of buying and then dramatically hiking the prices of low-cost drugs given to patients with life-threatening conditions including heart disease, AIDS and cancer, according to excerpts from ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.